Literature DB >> 21752914

APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Kenneth L Martin1, Megan Johnson, Richard T D'Aquila.   

Abstract

APOBEC3G (A3G) is packaged into human immunodeficiency virus type 1 (HIV-1) virions unless HIV-1 virion infectivity factor (Vif) counteracts it. Virion A3G restricts HIV-1 reverse transcription and integration in target cells. Some A3G in producer cells colocalizes with specific cytoplasmic structures, in what are called "A3G complexes" here. Functional effects of producer cell A3G complexes on HIV-1 replication were studied. HeLa cells were cotransfected with HIV-1 constructs producing pseudoviruses, as well as either wild-type (WT) A3G or a mutant A3G (C97A, Y124A, W127A, or D128K A3G). Pseudovirus particle production was decreased from cells expressing any of the A3Gs that formed complexes by 24 h after transfection, relative to cells with C97A A3G that did not form detectable A3G complexes by 24 h or A3G-negative cells. The intracellular HIV-1 Gag half-life was shorter in cells containing A3G complexes than in those lacking complexes. HIV-1 virion output was decreased in a single round of replication from a T cell line containing A3G complexes (CEM cells) after infection with Vif-negative HIV-1, compared to Vif-positive HIV-1 that depleted A3G. Levels of production of Vif-negative and Vif-positive virus were similar from cells not containing A3G (CEM-SS cells). Knockdown of the mRNA processing body (P-body) component RCK/p54, eliminated A3G complex formation, and increased HIV-1 production. We conclude that endogenous A3G complexes in producer cells decrease HIV-1 production if not degraded by Vif.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21752914      PMCID: PMC3165773          DOI: 10.1128/JVI.00273-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.

Authors:  Craig Pace; Jean Keller; David Nolan; Ian James; Silvana Gaudieri; Corey Moore; Simon Mallal
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Perplexing bodies: The putative roles of P-bodies in neurons.

Authors:  Manuel Zeitelhofer; Paolo Macchi; Ralf Dahm
Journal:  RNA Biol       Date:  2008-10-08       Impact factor: 4.652

3.  5' to 3' mRNA decay factors colocalize with Ty1 gag and human APOBEC3G and promote Ty1 retrotransposition.

Authors:  James A Dutko; Alison E Kenny; Eric R Gamache; M Joan Curcio
Journal:  J Virol       Date:  2010-03-10       Impact factor: 5.103

4.  Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction.

Authors:  Eric W Refsland; Mark D Stenglein; Keisuke Shindo; John S Albin; William L Brown; Reuben S Harris
Journal:  Nucleic Acids Res       Date:  2010-03-22       Impact factor: 16.971

5.  A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.

Authors:  Hongzhan Xu; Evguenia S Svarovskaia; Rebekah Barr; Yijun Zhang; Mohammad A Khan; Klaus Strebel; Vinay K Pathak
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-30       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant.

Authors:  Sandrine Opi; Sandra Kao; Ritu Goila-Gaur; Mohammad A Khan; Eri Miyagi; Hiroaki Takeuchi; Klaus Strebel
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

7.  Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.

Authors:  Kun Luo; Tao Wang; Bindong Liu; Chunjuan Tian; Zuoxiang Xiao; John Kappes; Xiao-Fang Yu
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

8.  APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker.

Authors:  Atuhani Burnett; Paul Spearman
Journal:  J Virol       Date:  2007-03-07       Impact factor: 5.103

9.  A single amino acid substitution of the human immunodeficiency virus type 1 capsid protein affects viral sensitivity to TRIM5 alpha.

Authors:  Ayumu Kuroishi; Katarzyna Bozek; Tatsuo Shioda; Emi E Nakayama
Journal:  Retrovirology       Date:  2010-07-07       Impact factor: 4.602

10.  Suppression of HIV-1 replication by microRNA effectors.

Authors:  Christine Chable-Bessia; Oussama Meziane; Daniel Latreille; Robinson Triboulet; Alessia Zamborlini; Alexandre Wagschal; Jean-Marc Jacquet; Jacques Reynes; Yves Levy; Ali Saib; Yamina Bennasser; Monsef Benkirane
Journal:  Retrovirology       Date:  2009-03-09       Impact factor: 4.602

View more
  13 in total

Review 1.  Inhibition and avoidance of mRNA degradation by RNA viruses.

Authors:  Stephanie L Moon; Michael D Barnhart; Jeffrey Wilusz
Journal:  Curr Opin Microbiol       Date:  2012-05-23       Impact factor: 7.934

2.  HIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodies.

Authors:  Prabhjeet K Phalora; Nathan M Sherer; Steven M Wolinsky; Chad M Swanson; Michael H Malim
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

3.  Manipulation of cellular processing bodies and their constituents by viruses.

Authors:  Asit K Pattnaik; Phat X Dinh
Journal:  DNA Cell Biol       Date:  2013-04-25       Impact factor: 3.311

4.  APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.

Authors:  Jinhui Li; Yan Chen; Ming Li; Michael A Carpenter; Rebecca M McDougle; Elizabeth M Luengas; Patrick J Macdonald; Reuben S Harris; Joachim D Mueller
Journal:  J Mol Biol       Date:  2013-12-17       Impact factor: 5.469

Review 5.  The APOBEC3 family of retroelement restriction factors.

Authors:  Eric W Refsland; Reuben S Harris
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

6.  Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity.

Authors:  Taisuke Izumi; Ryan Burdick; Mayu Shigemi; Sergey Plisov; Wei-Shau Hu; Vinay K Pathak
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

Review 7.  Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART.

Authors:  C W Peterson; P Younan; K R Jerome; H-P Kiem
Journal:  Gene Ther       Date:  2013-01-31       Impact factor: 5.250

8.  The double-domain cytidine deaminase APOBEC3G is a cellular site-specific RNA editing enzyme.

Authors:  Shraddha Sharma; Santosh K Patnaik; Robert T Taggart; Bora E Baysal
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

9.  Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.

Authors:  Cancan Chen; Xiaocao Ma; Qifei Hu; Xinghua Li; Feng Huang; Junsong Zhang; Ting Pan; Jinyu Xia; Chao Liu; Hui Zhang
Journal:  Retrovirology       Date:  2017-12-19       Impact factor: 4.602

Review 10.  Who Regulates Whom? An Overview of RNA Granules and Viral Infections.

Authors:  Natalia Poblete-Durán; Yara Prades-Pérez; Jorge Vera-Otarola; Ricardo Soto-Rifo; Fernando Valiente-Echeverría
Journal:  Viruses       Date:  2016-06-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.